Skip to main content
Interview with the Innovators
Lung Cancer
3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227
Read More
Lung Cancer
Combination of Chemotherapy with Nivolumab plus Ipilimumab in First-Line Advanced NSCLC (CheckMate-9LA)
Read More
Lung Cancer
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Read More
Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Read More
Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Read More
Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Read More
Lung Cancer
Unmet Needs in NSCLC
Read More
HOPA Highlights, Immunotherapy, Lung Cancer, Screening
The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer
Meg Barbor, MPH
Meg Barbor, MPH
Read More
Lung Cancer, FDA Updates
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Read More
Lung Cancer, FDA Updates
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
Page 10 of 12
Results 91 - 100 of 116